Duloxetine
Product Images NDC 45865-815

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 45865-815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (815)

Duloxetine DR Capsules 20 mg blister pack label by Medsource Pharmaceuticals, generic for Cymbalta. The label shows product NDC 45865-815, quantity 30 capsules, with instructions to take capsules daily. Manufactured by L.A.B. Dr. Esteve, S.A., Barcelona, Spain.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride showing its molecular framework with distinct aromatic rings, a thiophene, and the amine hydrochloride group.*

FDA Label Image

Figure 1 (Duloxetine 02)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time from randomization to relapse (in days) for two treatments: placebo and duloxetine. The graph shows the relapse proportion on the vertical axis and time in days on the horizontal axis, illustrating differences in relapse rates between the two groups over a period of approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time in days from randomization. It shows two treatment groups: Placebo (dashed line) and Duloxetine (solid line), tracking relapse rates up to approximately 250 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved relative to the percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The vertical axis shows the percentage of patients improved, while the horizontal axis represents the percent improvement in pain from baseline.*

FDA Label Image

Figure 4 (Duloxetine 05)

Line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. Three groups are shown: Duloxetine Delayed-Release 60 mg BID, Duloxetine Delayed-Release 60 mg QD, and placebo. The graph illustrates higher improvement percentages for Duloxetine groups compared to placebo across increasing pain improvement thresholds.*

FDA Label Image

Figure 7 (Duloxetine 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two data series are shown: Placebo and Duloxetine (DUL) 60/120 mg once daily. The graph illustrates a comparison of patient improvement rates across different pain improvement percentages.*

FDA Label Image

Figure 8 (Duloxetine 07)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows data for Placebo and Duloxetine Delayed-Release 60 mg once daily, illustrating patient improvement trends over different pain improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine 08)

A line graph comparing the percentage of patients improved over the percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release (DUL) 60/120 mg once daily versus placebo. The graph shows two lines: one with a diamond marker for Duloxetine and one with an "x" marker for placebo, illustrating efficacy differences across various pain improvement thresholds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.